Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: KEGG:D02052 (Barium sulfate)
 55 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Surgical management of osteoarthritis, aseptic necrosis and rheumatoid arthritis has been revolutionized by the introduction of acrylic cement-stabilized joint surface replacement. Although single joint surface replacements have been employed extensively for more than half a century, total surface replacement operations with a wear-resistant high-density polyethylene and noncorrosive stainless steel stabilized by acrylic cement were introduced only a little more than 12 years ago. This evolved with Charnley's discovery of the high level of bone tolerance for acrylic cement. Acrylic cement made it possible mechanically to bond artificial joint surfaces to the bone ends and produce an insensitive Charcot-like functioning joint. A barium sulfate additive makes the cement radiopaque for visualizing the bone-cement interface. Barium sulfate additive also lowers the polymerization temperature and opens the polymer for influx of interstitial fluids. Antibiotics have also been added to the cement for prevention and treatment of infection of the surrounding tissues. In aged individuals with cardiovascular disease, the absorption of the acrylic monomer depresses cardiac output and produces hypotension for 2-5 minutes after impaction of acrylic cement into spongy bone. The hypotension has been minimized by cautious fluid replacement and maintenance of adequate blood volume before, during and after the operation. Approximately 30,000 total hip arthroplasties are performed in the United States annually in patients older than 50 years of age with fractured femoral head replacements, bilateral rheumatoid arthritis, old neglected congenital dislocations of the hip or osteonecrosis with and without osteoarthritis. The pain relief is more complete and the functional improvement more predictable than in any other previously recommended surgical operation for the purpose. For this reason, total hip arthroplasty has almost completely supplanted mold-arthroplasty, osteotomy, capsulotomy (hanging hip) and resection of the femoral head. Hemiarthroplasty in the form of femoral head replacement still is the procedure of choice in patients with fractures of the neck of the femur and a normal acetabular articular cartilage, irrespective of age. As a countermeasure against loosening of the prosthesis in patients with osteoporosis and a hollow proximal end of the femur, the stem can be stabilized with acrylic cement. A standard replaceable femoral head for subsequent conversion of femoral head replacement to total hip arthroplasty is an important consideration and presently is under investigation in several medical centers.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:Acrylic cement stabilized joint replacements. 80 82

This study describes a clinical evaluation of the Progesterone T IUD which releases a daily dose of 65 mcg of progesterone. The device is made of a copolymer of ethylene vinyl and has a transversal arm measuring 3.18 cm and a longitudinal arm 3.61 cm. The longitudinal arm contains 38 mg of natural progesterone, Barium sulfate, and silicone acetate. 146 new users of the Progesterone T were compared with 149 using the Copper 7 Gravigarde. Patients in both groups ranged in age from 17-40 years with an average of 27.2 for Progesterone T and 27.1 for Copper 7 users. Parity ranged from 1-11 with an average of 2.8 for the Progesterone T group and from 1-10 with an average of 2.7 for the Copper 7 group. The average number of spontaneous abortions was .7 for the Progesterone T group and .5 for the Copper 7 group. The groups were also comparable in previous contraceptive usage. In another study, 51 Lippes Loop D users, 52 Progesterone T users, and 50 Copper 7 users were evaluated for menstrual and intermenstrual blood loss in the 3 months prior to and the 1st, 2nd, 4th, 6th, 9th, and 12th months after insertion. At the end of 12 months, the Progesterone T and Copper 7 users respectively had pregnancy rates of 1.4 and 1.5, expulsion rates of 4.2 and 5.8, rates of removal for medical reasons of 2.8 and 3.0, and continuation rates of 87.2 and 84.6. After 1569 women-months of Progesterone T use and 1558 of Copper 7 use there were no statistically significant differences. With the Progesterone T there was 1 removal for pain, 1 for pelvic inflammation, and 2 for menstrual alterations. 4 Copper 7s were removed for bleeding. The average duration of menstrual bleeding was 6.0 days with the Progesterone T and 6.2 with the Copper 7. The number of days of true bleeding were 4.8 on average for the Progesterone T and 5.3 for the Copper 7. Intermenstrual bleeding was twice as common for the Progesterone T. There was no statistically significant difference in incidence of pain reported by the 2 groups at the beginning and end of the study. Both groups had a decline in pain at the end of the study, with the Progesterone T having a slightly more pronounced decline. The average volume of menstrual blood loss increased by 87.8% after insertion of the Lippes Loop D and by 24.3% with the Copper 7 but declined by 44.5% for the Progesterone T.
 ...
PMID:[Clinical evaluation of the progesterone T intrauterine device]. 676 70